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Abstract
Background The predictive value of T-wave alternans
(TWA) for lethal ventricular tachyarrhythmia in patients
with left ventricular (LV) dysfunction is controversial.
Also, long-term arrhythmia risk of patients ineligible for
the TWA test is unknown.
Methods This was a multicenter, prospective observa-
tional study of patients with LV ejection fraction B40%
due to ischemic or non-ischemic cardiomyopathies,
designed to evaluate the prognostic value of TWA for
lethal ventricular tachyarrhythmia. The primary end point
was a composite of sudden cardiac death, sustained rapid
ventricular tachycardia (VT) or ventricular ﬁbrillation
(VF), and appropriate deﬁbrillator therapy for rapid VT or
VF.
Results Among 453 patients enrolled in the study, 280
(62%) were eligible for the TWA test. TWA was negative
in 82 patients (29%), who accounted for 18% of the total
population. The median of follow-up was 36 months. The
3-year event-free rate for the primary end point was sig-
niﬁcantly higher in TWA-negative patients (97.0%) than in
TWA non-negative patients (89.5%, P = 0.037) and those
ineligible for the TWA test (84.4%, P = 0.003). Multi-
variable analysis identiﬁed both non-negative TWA [haz-
ard ratio (HR) 4.43; 95% conﬁdence interval (CI)
1.02–19.2; P = 0.047) and ineligibility for the TWA test
(HR 6.89; 95% CI 1.59–29.9; P = 0.010) to be indepen-
dent predictors of the primary end point.
Conclusions TWA showed high negative predictive
ability for lethal ventricular tachyarrhythmia in patients
with LV dysfunction, although the TWA-negative patients
accounted for only 18% of the entire population. Those
ineligible for the TWA test had the highest risk for lethal
ventricular tachyarrhythmia.
Investigators of the PRospective Evaluation of VENtricular
Tachyarrhythmic events and Sudden Cardiac Death in patients with
left ventricular dysfunction (PREVENT-SCD) study are listed in
Appendix 1.
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Introduction
Recent randomized controlled trials have demonstrated the
mortality beneﬁt of an implantable cardioverter-deﬁ-
brillator (ICD) over optimal medical therapy in patients
with left ventricular (LV) dysfunction [1, 2]. The Multi-
center Automatic Deﬁbrillator Implantation Trial (MADIT)
II showed 31% reduction in relative risk of mortality
among patients with prior myocardial infarction and a LV
ejection fraction (LVEF) B30% [1]. The Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) showed 23%
reduction in relative risk of mortality in patients with
LVEF B35% and New York Heart Association (NYHA)
class II–III congestive heart failure due to ischemic or non-
ischemic etiology [2].
Despite the signiﬁcant reduction in mortality shown in
MADIT II and SCD-HeFT, the absolute beneﬁts were
relatively small: 5.6% over 20 months and 7.2% over
5 years, respectively [1, 2]. Because of concerns not only
for the potential side effects of ICD [3–5] but also for the
huge economic burden, further risk stratiﬁcation to identify
patients who are likely or unlikely to beneﬁt from ICD
seems to be necessary.
Microvolt-level T-wave alternans (TWA) in a body-
surface electrocardiogram (ECG) was proposed as a non-
invasive method to evaluate risk of sudden cardiac death
(SCD) or lethal ventricular tachyarrhythmia [6]. Although
high negative predictive values of TWA have been repor-
ted [6–11], recent studies have reported conﬂicting data on
the prognostic value of TWA [12–14]. Furthermore, TWA
cannot be assessed in patients with persistent atrial ﬁbril-
lation (AF), ventricular pacing or exercise intolerance, who
account for a sizable portion of the entire population of
patients with LV dysfunction [15–17].
To address these issues, we have conducted a multi-
center, prospective study assessing the predictive value of
TWA for SCD or lethal ventricular tachyarrhythmia in a
broad population of Japanese patients with LV dysfunction,
including those ineligible for the TWA test.
Methods
Study design and patient enrollment
The Prospective Evaluation of Ventricular Tachyarrhyth-
mic Events and Sudden Cardiac Death in Patients with Left
Ventricular Dysfunction (PREVENT-SCD) study is a
prospective multicenter registry of Japanese patients with
LV dysfunction, designed to evaluate the prognostic value
of TWA and other potential arrhythmia risk factors for
ventricular tachyarrhythmia. The study design is shown in
Fig. 1.
Patients with LVEF B40% without treatable cardiac
ischemia, who had NYHA class I–III heart failure, were
eligible for the study. All patients had to be maintained on
an optimal dose of angiotensin-converting enzyme inhibi-
tors or angiotensin receptor blockers and beta-blockers
before enrollment in the study unless these drugs were
contraindicated or patients were intolerant.
Patients were excluded if they had a history of sustained
ventricular ﬁbrillation (VF) or ventricular tachycardia
(VT), had previous ICD implantation, had NYHA class IV
heart failure, had a myocardial infarction (MI) within the
past month, had undergone coronary revascularization
within the past 3 months, had treatable cardiac ischemia,
had scheduled coronary revascularization or cardiac sur-
gery, or had any condition other than cardiac disease with
expectation of survival less than 1 year.
LV function was assessed by echocardiography using
modiﬁed Simpson’s method. When echocardiography was
considered inappropriate due to poor images, then mag-
netic resonance imaging, angiography or radionuclide
scanning was used to assess LV function.
Fig. 1 Study design of the PREVENT-SCD study
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123Ischemic cardiomyopathies were deﬁned as LV dys-
function associated with a documented history of MI or
severe narrowing of at least one of the three major coronary
arteries. The others were classiﬁed as non-ischemic car-
diomyopathies. Absence of treatable cardiac ischemia was
conﬁrmed by a stress test and/or coronary angiography.
Between June 2004 and February 2007, a total of 453
patients were enrolled from 38 centers in Japan (Appendix
1). Patients were scheduled to undergo TWA and other risk
stratiﬁcation tests, including 12-lead ECG and Holter ECG
as mandatory tests and signal-averaged ECG and electro-
physiological (EP) study as optional tests. Therapeutic
strategies based on the results of the risk stratiﬁcation tests
were determined within 2 months of enrollment. The
choice of therapeutic strategy, such as ICD implantation,
was left to the discretion of the attending physicians.
Device programming in ICD patients was not prespeciﬁed
in this study. Case-speciﬁc programming was made at
individual centers.
The relevant review boards or ethics committees in all
participating centers approved the research protocol.
Written informed consent was obtained from all patients.
Risk stratiﬁcation tests
The TWA test was performed in all eligible patients.
Patients underwent the TWA test while taking their regular
medication, including beta-blockers. Careful skin prepara-
tion was performed and high-resolution electrodes were
used to minimize noise. ECG leads were placed at the
standard 12-lead positions and in an orthogonal X, Y and Z
conﬁguration. Measurements were made with a CH2000 or
Heartwave system (Cambridge Heart Inc., Bedford, MA,
USA). The result of the TWA test was automatically
interpreted by the Alternans Report Classiﬁer within the
CH2000 or Heartwave system, reviewed by EP cardiolo-
gists at each individual center, and classiﬁed into positive,
negative or indeterminate according to previously descri-
bed criteria [18].
Because patients with indeterminate and positive TWA
tests have been reported to have a similar arrhythmic or
mortality risk [19], they were prospectively combined for
analysis as ‘non-negative’ TWA tests. In this study,
therefore, comparisons were made among patients with
negative TWA, patients with non-negative (positive or
indeterminate) TWA, and those ineligible for the TWA
test.
Resting 12-lead ECG was evaluated for basic cardiac
rhythm, heart rate, QRS duration, and QRS morphology.
Holter ECG was evaluated for number of premature ven-
tricular contractions (PVCs), as well as the presence or
absence of non-sustained VT (NSVT). NSVT was deﬁned
as 3-30 PVCs at a rate[100/min.
Other potential arrhythmia risk predictors included age,
sex, etiology of LV dysfunction, NYHA class, diabetes,
hypertension, hyperlipidemia, AF, ventricular pacing,
blood pressure, LVEF, LV end-diastolic dimension
(LVEDD), mitral regurgitation, renal failure, anemia, brain
natriuretic peptide (BNP) level and medication at the time
of enrollment.
Follow-up and end points
All patients were followed in each participating center at
least yearly after enrollment, either by hospital visits or
telephone contact with the patients. When clinical events
were suspected by telephone interview with the patients,
they were conﬁrmed by contact with the referring physi-
cians. All ICD patients were followed at least every
6 months by hospital visits, and all ICD data were obtained
by interrogation of the device. Clinical data were pro-
spectively collected according to pre-speciﬁed deﬁnitions.
The prespeciﬁed primary end point of the study was a
severe ventricular tachyarrhythmic event (SVTE), deﬁned
as a composite of SCD, sustained rapid-VT (C188/min) or
VF, and appropriate ICD therapy for rapid-VT (C188/min)
or VF. The secondary end points were all-cause death,
cardiac death, and a ventricular tachyarrhythmic event
(VTE) deﬁned as a composite of SVTE, sustained VT
(\188/min) and appropriate ICD therapy for VT (\188/
min). SCD was deﬁned as unexpected natural death
occurring instantaneously or within 24 h of the onset of
acute symptoms or signs, of which the cause was proved to
be cardiac at necropsy or assumed to be cardiac because of
clinical circumstances. Unwitnessed death of unknown
cause was also regarded as SCD.
All of the primary and secondary events were adjudi-
cated by a clinical events committee (Appendix 2).
Statistical analyses
All continuous variables are expressed as mean ± SD or
median. Statistical signiﬁcance between the groups was
assessed by Student’s t test for parametrically distributed
continuous variables, the Wilcoxon rank sum test for non-
parametrically distributed continuous variables, and Pear-
son’s v
2 test for categorical variables.
Event-free survival was calculated by the Kaplan–Meier
method. The signiﬁcance of differences in event-free sur-
vival between groups was assessed with a log-rank test.
Cox proportional hazards models were used to identify
independent predictors of SVTE. Two dummy variables
were created to reﬂect three levels of TWA status in the
cohort: a negative test, a non-negative (positive or inde-
terminate) test, and no test (ineligible for the TWA test).
The continuous variables were dichotomized by clinically
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123meaningful reference values or median values. We ﬁrst
selected variables with P values \0.1 in the univariable
Cox models and then included them simultaneously in the
multivariable models. Patients with missing values for any
selected variable were excluded from the multivariable
analysis. The independent predictors of SVTE were iden-
tiﬁed by the forward and backward stepwise methods with
inclusion and exclusion P values\0.05. Relative risks are
expressed as hazard ratios (HRs) with 95% conﬁdence
intervals (CIs). All tests were 2-sided, and a P value\0.05
was considered statistically signiﬁcant.
Results
Patient characteristics
The clinical characteristics of the 453 patients enrolled in
the PREVENT-SCD study are listed in Table 1. The
average age was 65.1 ± 12.6 years, and 367 (81%) were
male. The etiology was ischemic in 189 (42%) and non-
ischemic in 264 (58%). The mean LVEF was 29.2 ± 7.4%.
Among the 189 ischemic patients, 170 (90%) had had prior
coronary revascularization.
TWA could be evaluated in 280 patients (62%), and the
results were negative in 82 (29%), positive in 138 (49%),
and indeterminate in 60 (21%). The TWA test was per-
formed by an exercise test in 251 patients (90%) and by
atrial pacing in 29 (10%). The reason for ineligibility for
the TWA test was presence of AF in 65 patients (38%),
presence of ventricular pacing in 34 (20%), presence of
both AF and ventricular pacing in 12 (7%), exercise
intolerance in 50 (29%), and other causes in 12 (7%). The
reason for the indeterminate TWA results was an inade-
quate heart rate increase in 29 patients (48%), frequent
ectopies in 13 (22%), excessive noise in 10 (17%), and
other causes in 8 (13%).
Resting 12-lead ECG was available in all patients.
Forty-four percent of patients had QRS duration C120 ms.
Holter monitoring was performed in 433 patients (95%).
PVC[10/h and NSVT were documented in 53 and 36%,
respectively.
ICD was implanted in 111 patients (25%), 46 of which
were in combination with cardiac resynchronization
therapy.
Table 2 shows comparison of patients according to TWA
status. TWA-non-negative patients had a higher prevalence
of frequent PVCs than TWA-negative patients. Those
ineligible for the TWA test were older, were associated with
more severe heart failure symptoms, had higher BNP levels,
had a wider QRS duration, and had a higher prevalence of
AF or digitalis use as compared with TWA-negative
patients. An ICD was used more often in TWA non-nega-
tive patients than in TWA-negative patients.
Long-term clinical outcome
During the median follow-up of 36 months (interquartile
range 27–41 months), there were 47 ﬁrst SVTEs, 70 ﬁrst
VTEs, and 68 deaths including 44 cardiac deaths (Table 3).
Figure 2 shows the event-free curves for the primary end
point of SVTE according to TWA status. The event-free
rate for SVTE in TWA-negative patients was high, 100% at
1 year, 98.6% at 2 years, and 97.0% at 3 years. Both TWA-
non-negative patients and those ineligible for the TWA test
had signiﬁcantly worse 3-year event-free rates for SVTE as
compared with TWA-negative patients (89.5% with
P = 0.037 and 84.4% with P = 0.003, respectively). When
TWA-non-negative patients were separated into TWA-
indeterminate and TWA-positive patients, the correspond-
ing 3-year event-free rate for SVTE was 92.5% (P = 0.22)
and 88.1% (P = 0.02), respectively. Among patients inel-
igible for the TWA test, those with AF, ventricular pacing
or exercise intolerance had similar 3-year event-free rates
for SVTE (81.2, 85.7, and 86.5%, respectively; P = 0.72).
Univariable and multivariable predictors of the primary
end point are shown in Table 4. Multivariable analysis
identiﬁed both non-negative TWA (HR 4.43; 95% CI
1.02–19.2; P = 0.047) and ineligibility for the TWA test
(HR 6.89; 95% CI 1.59–29.9; P = 0.010) to be indepen-
dent predictors of SVTE. When non-negative TWA was
separated into indeterminate and positive TWA, the cor-
responding adjusted HR for indeterminate and positive
TWA was 2.67 (95% CI 0.48–14.7; P = 0.26) and 5.36
(95% CI 1.22–23.7; P = 0.027), respectively. There was
no signiﬁcant interaction between TWA status and other
clinical variables, including age, etiology of LV dysfunc-
tion, LVEF and QRS duration (Table 5).
Event-free curves for the secondary end points are
shown in Fig. 3. Those ineligible for the TWA test had
signiﬁcantly worse event-free rates for all secondary end
points as compared with TWA-negative patients with a HR
of 3.15 for VTE (95% CI 1.33–7.47), 3.57 for all-cause
death (95% CI 1.40–9.11), and 12.5 for cardiac death (95%
CI 1.69–91.9). TWA-non-negative patients had signiﬁ-
cantly worse cardiac survival than TWA-negative patients
(HR 7.71; 95% CI 1.04–57.7).
TWA negative patients had higher 3-year event-free rate
for a composite of all-cause death and SVTE (91.9%) as
compared with TWA-non-negative patients (81.7%,
P = 0.03) and those ineligible for the TWA test (74.5%,
P = 0.0004). The 3-year event-free rate for cardiac death or
SVTEwas97.0,86.2(P = 0.008),and78.9%(P\0.0001),
respectively.
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The present study focused on the predictive value of TWA
for lethal ventricular tachyarrhythmia in a broad population
of patients with LV dysfunction. The event-free rate for
SVTE in TWA-negative patients was excellent, 100% at
1 year, 98.6% at 2 years, and 97.0% at 3 years, which may
suggest that TWA-negative patients can be safely excluded
as ICD candidates. When those ineligible for the TWA test
were taken into account, however, the TWA-negative
patients accounted for only 18% of the entire study popu-
lation. Thus, despite the strikingly high negative predictive
value of TWA for SVTE, the safety assurance afforded by
a negative result of the TWA test was applicable to only a
limited proportion of patients with LV dysfunction.
The other important ﬁnding of this study was the poor
long-term prognosis of patients ineligible for the TWA test.
Ineligibility for the TWA test was associated with highest
risk not only for the primary end point of SVTE but for all
of the secondary end points, including VTE, all-cause
death and cardiac death.
All previous TWA studies have excluded patients inel-
igible for the TWA test. Exclusion of those patients might
be associated with considerable selection bias toward
patients with good exercise capacity and those without AF
or ventricular pacing. Although the prevalence of negative
TWA among eligible patients with LV dysfunction has
been reported to be 22–37% [8–14], a value coincident
with the 29% observed in the present study, the proportion
of TWA-negative patients among all patients with LV
dysfunction has not previously been established. In addi-
tion, the long-term arrhythmia and mortality risk of
patients ineligible for the TWA test has been uncertain. To
the best of our knowledge, our study is the ﬁrst multicenter
study evaluating the prognostic utility of TWA in a real-
Table 1 Patient characteristics
Baseline characteristics
Age 65.1 ± 12.6
Male 367 (81%)
NYHA-III 128 (28%)
Ischemic 189 (42%)
Non-ischemic 264 (58%)
Risk factors and co-morbidities
Prior MI 180 (40%)
CABG/PCI 170 (38%)
Stroke or TIA 41 (9%)
Diabetes 125 (28%)
Hypertension 207 (46%)
Hyperlipidemia 144 (32%)
AF 120 (26%)
Persistent AF 65 (14%)
Pacemaker 56 (12%)
Systolic BP (mmHg) 119 ± 22
Systolic BP\100 mmHg 74 (16%)
Diastolic BP (mmHg) 69 ± 12
Hemoglobin\12 g/dL 108 (24%)
eGFR\40 mL/min/1.73 m
2 90 (20%)
BNP (pg/mL) 211
BNP C200 pg/mL 228 (52%)
Echocardiography
LVEF (%)
a 29.2 ± 7.4
LVEF B30% 228 (50%)
LVEDD (mm) 62.3 ± 8.9
LVEDD C70 mm 90 (20%)
MR grade 3 or 4 58 (13%)
Medications
ACEIs or ARBs 375 (83%)
Beta-blockers 331 (73%)
Diuretics 350 (77%)
Spironolactone 236 (52%)
Digitalis 139 (31%)
Amiodarone 81 (18%)
Aspirin 229 (51%)
Statin 131 (29%)
Risk stratiﬁcation tests
TWA (N = 280)
Negative 82 (29%)
Positive 138 (49%)
Indeterminate 60 (21%)
Resting 12-lead electrocardiogram (N = 453)
Heart rate (/min) 71
QRS (ms) 113
QRS C120 ms 199 (44%)
Holter monitoring (N = 433)
PVC[10/h 231 (53%)
NSVT 157 (36%)
Table 1 continued
Antiarrhythmic therapies
ICD 111 (25%)
ICD with CRT 46 (10%)
ACEIs angiotensin-converting enzyme inhibitors, AF atrial ﬁbrilla-
tion, ARBs angiotensin receptor blockers, BNP brain natriuretic
peptide, BP blood pressure, CABG coronary artery bypass grafting,
CRT cardiac resynchronization therapy, eGFR estimated glomerular
ﬁltration rate, ICD implantable cardioverter-deﬁbrillator, LVEDD left
ventricular end-diastolic dimension, LVEF left ventricular ejection
fraction, MI myocardial infarction, MR mitral regurgitation, NSVT
non-sustained ventricular tachycardia, NYHA New York Heart
Association, PCI percutaneous coronary intervention, PVC premature
ventricular contraction, TIA transient ischemic attack, TWA T-wave
alternans
a Measured by modiﬁed Simpson’s method. For 33 patients with poor
echo images, magnetic resonance imaging was used in 15 patients,
angiography in 15 patients, and radionuclide scanning in 3 patients
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123world population of LV dysfunction patients, including
those ineligible for the TWA test. TWA showed high
negative predictive ability for lethal ventricular tachyar-
rhythmia and cardiac mortality, but the proportion of
TWA-negative patients was less than one-ﬁfth of the entire
study population. Those ineligible for the TWA test had
highest arrhythmia and mortality risk.
To date, seven multicenter studies assessing the pre-
dictive value of TWA for lethal ventricular tachyarrhyth-
mia in patients with LV dysfunction have been reported
(Supplementary Table) [8–14]. Four of those studies
reported the signiﬁcant prognostic utility of TWA with
high negative predictive values for arrhythmic events [8–
11], as shown in our study. However, the other three more
recent studies have reported conﬂicting data on the pre-
dictive value of TWA [12–14]. The Microvolt T Wave
Alternans Testing for Risk Stratiﬁcation of Post-Myocar-
dial Infarction Patients (MASTER) trial and the SCD-
HeFT substudy showed no difference in arrhythmic event
rates between TWA-negative and TWA-non-negative
patients [12, 13]. Furthermore, in the Alternans Before
Cardioverter Deﬁbrillator (ABCD) trial, TWA showed
Fig. 2 Event-free curves for the primary end point of SVTE
according to TWA status
Table 2 Comparison of patients according to TWA status
TWA-negative (N = 82) TWA-non-negative (N = 198) Ineligible for TWA (N = 173)
Age 60.5 ± 15.4 63.8 ± 12.3 68.7 ± 10.2

Ischemic 41 (50%) 94 (57%) 54 (31%)

NYHA-III 13 (16%) 34 (17%) 81 (47%)

AF 6 (7%) 21 (11%) 93 (54%)

Systolic BP (mmHg) 120 ± 23 120 ± 20 117 ± 23
Hemoglobin (g/dL) 13.6 ± 1.8 13.4 ± 3.2 13.3 ± 2.2
BNP (pg/mL) 155 174 286

LVEF (%) 29.8 ± 7.2 29.2 ± 7.2 28.8 ± 7.6
LVEDD (mm) 61.2 ± 8.0 63.2 ± 8.9 61.7 ± 9.2
MR grade 3 or 4 8 (10%) 23 (12%) 27 (16%)
Digitalis 21 (26%) 41 (21%) 77 (45%)
QRS (ms) 103 109 127

PVC[10/h 31 (39%) 105 (54%)* 95 (60%)

NSVT 25 (31%) 66 (34%) 66 (42%)
ICD 12 (15%) 60 (30%)* 39 (23%)
Abbreviations as in Table 1
* P\0.05;
 P\0.005 in comparison with TWA-negative group
Table 3 Primary and secondary end points during follow-up
First SVTE 47 (10.4%)
SCD 15
a
Sustained rapid-VT/VF (C188/min) 8
ICD therapy for rapid-VT/VF (C188/min) 24
First VTE 70 (15.5%)
SVTE 31
b
Sustained VT (\188/min) 3
ICD therapy for VT (\188/min) 36
Death 68 (15.0%)
Cardiac death 44 (9.7%)
SCD 17 (3.8%)
SCD sudden cardiac death, SVTE severe ventricular tachyarrhythmic
event, VF ventricular ﬁbrillation, VT ventricular tachycardia, VTE
ventricular tachyarrhythmic event
a Out of 17 SCDs, 15 were ﬁrst SVTE
b Out of 47 SVTEs, 31 were ﬁrst VTE
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123limited predictive ability for lethal ventricular tachyar-
rhythmia. The difference in the primary event rates
between TWA-negative and TWA-non-negative patients
was signiﬁcant up to 9 months, but no longer after
12 months [14].
There are several possible explanations for these con-
ﬂicting results. First, among the studies there were sub-
stantial differences in TWA protocol, which might have
inﬂuenced the predictive accuracy of the TWA test. In four
studies including MASTER, SCD-HeFT and ABCD, beta-
blockers were withheld for C24 h before the TWA test in
order to reduce indeterminate TWA results due to an
inadequate heart rate increase during exercise. However,
Klingenheben et al. [20] reported that metoprolol and
sotalol decreased TWA amplitude by 35 and 38%,
respectively. Also, in a study by Rashba et al. [21], intra-
venous beta-blocker of esmolol reduced the number of
positive TWA tests by 50%. These data suggest that beta-
blockers should be continued at the time of the TWA test.
In a recent meta-analysis of TWA studies by Chan et al.
[22], non-negative TWA was associated with a ﬁvefold
increased risk for ventricular tachyarrhythmia as compared
with negative TWA in studies where beta-blockers were
continued during the TWA test, while only a much weaker
association was observed in studies where beta-blockers
were withheld prior to the TWA test.
Second, it may be that previous studies did not exclude
patients with treatable cardiac ischemia, which could affect
the prognostic value of the TWA test. Patients with heavy
ischemic burden are considered to have higher risk for a
future coronary event, which is often associated with lethal
ventriculartachyarrhythmiainpatients withLVdysfunction
[23]. In the present study, coronary artery disease was well
treated among ischemic patients, none of whom had treat-
able cardiac ischemia.
Third, the prevalence of ICD use was much higher in
MASTER and ABCD, 100 and 87%, respectively, as com-
pared with 25% in the present study. The use of appropriate
ICD therapy for ventricular tachyarrhythmia as a surrogate
end point for SCD may overestimate arrhythmic events, by
counting potential self-terminating tachycardia as events
[24]. Thus, a higher prevalence of ICD use may lead to a
higher possibility of overestimating arrhythmic events.
The low prevalence of ICD use in the present study was
largely due to the fact that reimbursement ofﬁcially covers
ICDs only for secondary prevention of SCD in Japan.
Because patient enrollment of this study started in June
2004, when the results of MADIT II and SCD-HeFT had
been already published or announced, therapeutic strategies
(i.e., whether to implant ICD or not) were left to the dis-
cretion of the attending physician. As a result, ICD patients
were much sicker than Non-ICD patients in terms of lower
systolic blood pressure, higher BNP level, lower LVEF,
larger LVEDD, wider QRS duration, lower prevalence of
negative-TWA, and higher prevalence of moderate to
severe mitral regurgitation, PVC[10/h, or NSVT (data not
shown).
The TWA test was initially developed as risk stratiﬁ-
cation test for lethal ventricular tachyarrhythmia mainly in
ischemic patients [6–8], but recent studies indicate that
predictive values of TWA might be higher in non-ischemic
patients than in ischemic patients [9, 13]. Consistently, in
the present study, the negative predictive value of TWA for
SVTE was 100% in non-ischemic patients, as compared
Table 4 Univariable and
multivariable predictors of
SVTE
CI conﬁdence interval, HR
hazard ratio. Other
abbreviations as in Table 1
Variables Univariable analysis Multivariable analysis
Unadjusted HR (95% CI) P value Adjusted HR (95% CI) P value
TWA
Ineligible 6.69 (1.59–28.2) 0.010 6.89 (1.59–29.9) 0.010
Non-negative 4.15 (0.97–17.8) 0.056 4.43 (1.02–19.2) 0.047
MR grade 3 or 4 4.69 (2.56–8.61) \0.001 3.61 (1.80–7.27) \0.001
Age\65 years 1.70 (0.95–3.02) 0.072 2.48 (1.32–4.68) 0.005
Systolic BP\100 mmHg 2.91 (1.58–5.38) 0.001 2.43 (1.25–4.73) 0.009
PVC[10/h 3.01 (1.52–5.95) 0.002 2.35 (1.16–4.76) 0.017
NSVT 2.56 (1.41–4.64) 0.002 – –
LVEDD C70 mm 2.22 (1.21–4.06) 0.010 – –
BNP C200 pg/mL 2.13 (1.14–3.96) 0.017 – –
QRS C120 ms 1.91 (1.07–3.40) 0.029 – –
AF 1.87 (1.04–3.37) 0.037 – –
Digitalis 1.78 (1.00–3.16) 0.050 – –
LVEF B35% 2.12 (0.90–4.96) 0.060 – –
Hemoglobin\12 g/dL 1.75 (0.95–3.23) 0.087 – –
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123with 95.1% in ischemic patients, although the difference
was not statistically signiﬁcant (Table 5).
Because follow-up duration of previous studies report-
ing high predictive values of TWA ranged from 17 to
20 months [6–11], it has been uncertain whether the
prognostic utility of TWA remains robust beyond 2 years.
In the present study, the median of follow-up was
36 months, which was the longest among the multicenter
TWA studies. The 3-year event-free rates for SVTE and
cardiac death in TWA-negative patients were extremely
high, 97.0 and 98.6%, respectively. Our data suggest that
the predictive value of TWA remains robust over 3 years.
Limitations
The present study has several important limitations. First,
the number of patients enrolled in this study was not large
enough, considering the broad spectrum of its patient
population. Second, the number of patients screened and
excluded in this study was not recorded. Considering the
relatively slow rate of patient enrolment, there may be
some selection bias in our study population. Third, inclu-
sion of appropriate ICD therapy in the composite primary
end point may overestimate arrhythmic events, as dis-
cussed above. However, the prevalence of ICD use in the
Table 5 Risk of SVTE
according to TWA status in
patient subgroups
* P for interaction between
TWA and each variable based
on difference in probabilities of
events; TWA-negative versus
TWA-non-negative (left) and
TWA-negative versus ineligible
for TWA (right)
a Indeterminate because of no
events in TWA-negative group
Subgroups Events/n (%) Hazard ratio (95% CI) Interaction P*
Age 0.09/0.20
\65 years
TWA-negative 1/46 (2.2%)
TWA-non-negative 13/91 (14.3%) 7.69 (1.01–58.8)
Ineligible for TWA 12/58 (20.7%) 11.21 (1.46–86.2)
C65 years
TWA-negative 1/36 (2.8%)
TWA-non-negative 6/107 (5.6%) 1.92 (0.23–16.0)
Ineligible for TWA 14/115 (12.2%) 4.44 (0.58–33.8)
Etiology of LV dysfunction 0.19/0.10
Ischemic
TWA-negative 2/41 (4.9%)
TWA-non-negative 8/94 (8.5%) 1.87 (0.40–8.79)
Ineligible for TWA 6/54 (11.1%) 2.38 (0.48–11.8)
Non-ischemic
TWA-negative 0/41 (0%)
TWA-non-negative 11/104 (10.6%) –
a
Ineligible for TWA 20/119 (16.8%) –
a
LVEF 0.19/0.05
B35%
TWA-negative 1/63 (1.6%)
TWA-non-negative 17/160 (10.6%) 7.06 (0.94–53.09)
Ineligible for TWA 23/130 (17.7%) 12.52 (1.69–92.74)
[35%
TWA-negative 1/19 (5.3%)
TWA-non-negative 2/38 (5.3%) 1.06 (0.14–12.51)
Ineligible for TWA 3/43 (7.0%) 1.30 (0.10–11.71)
QRS duration 0.46/0.05
C120 ms
TWA-negative 0/24 (0%)
TWA-non-negative 7/72 (9.7%) –
a
Ineligible for TWA 20/103 (19.6%) –
a
\120 ms
TWA-negative 2/58 (3.4%)
TWA-non-negative 12/126 (9.5%) 2.91 (0.51–12.6)
Ineligible for TWA 6/70 (8.6%) 2.51 (0.65–13.0)
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123present study was relatively low as compared with other
recent studies. Fourth, the rate of self-terminating ventric-
ular tachycardia in patients without an ICD could not be
determined. Fifth, device programming in ICD patients
was not prespeciﬁed in this study. All intra-cardiac ECGs
of ICD therapies were, however, reviewed by the clinical
events committee. Finally, the results of the TWA test were
determined at each participating center without a core
laboratory so that the data would more closely represent
general clinical practice. Conversely, there may be some
heterogeneity in the interpretation of the TWA test results.
Conclusions
The present study demonstrated high negative predictive
ability of TWA for lethal ventricular tachyarrhythmia in a
real-world Japanese population of LV dysfunction patients
during the median follow-up of 3 years. However, the
TWA-negative patients accounted for only 18% of the
entire population, including those ineligible for the TWA
test. Thus, despite the strikingly high negative predictive
value of TWA for lethal ventricular arrhythmia, the safety
assurance given by a negative result of the TWA test was
applicable to only a limited proportion of patients with LV
dysfunction.
Those ineligible for the TWA test were associated with
highest risk for lethal ventricular tachyarrhythmia, as well
as highest overall and cardiac mortality.
Our study warrants further investigation with a larger
patient population and a longer follow-up period.
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Appendix 1: List of participating centers
and investigators
The following centers and investigators participated in the
PREVENT-SCD study (listed in alphabetical order
according to center):
Ehime Prefectural Central Hospital: Yukio Kazatani,
Shinichi Hiramatsu, Tsuyoshi Matsunaka, Sumiko Sato;
Fujita Health University Hospital: Hitoshi Hishida, Eiichi
Watanabe; Funabashi Municipal Medical Center: Shun
Ozawa, Masayuki Inagaki; Himeji Cardiovascular Center:
Teishi Kajiya, Kohei Yamashiro, Katsunori Okajima;
Hirosaki University School of Medicine & Hospital: Ken
Okumura, Atsushi Iwasa, Masaomi Kimura, Hyogo Pre-
fectural Amagasaki Hospital: Yoshiki Takatsu, Ryoji
Taniguchi; International Medical Center of Japan: Mitsuo
Kashida, Osamu Okazaki; Kagoshima University Medical
Fig. 3 Event-free curves for the
secondary end points according
to TWA status. Event-free
curves for VTE (a), all-cause
death (b) and cardiac death (c)
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123And Dental Hospital: Chuwa Tei, Shuichi Hamasaki,
Kobe University Hospital: Mitsuhiro Yokoyama, Akihiro
Yoshida; Kokura Memorial Hospital: Masakiyo Nobuyo-
shi, Kenji Ando, Hitoshi Okabayashi, Jyota Nakano;
Kurashiki Central Hospital: Kazuaki Mitsudo Satoki Fujii;
Kurume University Hospital: Teruhisa Yoshida, Yasut-
sugu Nagamoto, Eiichi Takii; Kyorin University Hospial:
Hideaki Yoshino, Takanori Ikeda; Kyoto University
Graduate School of Medicine: Takeshi Kimura, Satoshi
Shizuta, Yoshisumi Haruna, Takahiro Doi, Yukiko
Nishio, Neiko Ozasa, Kei Nishiyama, Toru Kita, Takeshi
Morimoto; Kyoto-Katsura Hospital: Shigeru Nakamura,
Yoshihisa Enjoji; Mitsubishi Kyoto Hospital: Shinji Miki,
Yutaka Kono; Nagoya University Hospital: Toyoaki
Murohara, Yasuya Inden; National Defense Medical
College Hospital: Fumitaka Ohsuzu, Koh Arakawa; Nii-
gata University Medical & Dental Hospital: Yoshifusa
Aizawa, Hiroshi Furushima; Nippon Medical School
Hospital: Takao Kato, Yoshinori Kobayashi; Oita Uni-
versity Hospital: Tetsunori Saikawa, Naohiko Takahashi;
Okayama University Hospital: Tohru Ohe, Satoshi Nag-
ase; Ome Municipal General Hospital: Kenichiro Otomo;
Sakurabashi Watanabe Hospital: Hiroshi Ito, Koichi
Inoue; Shiga University of Medical Science Hospital:
Minoru Horie, Takashi Yamamoto, Masanori Fujii,
Makoto Ito; Showa University Fujigaoka Hospital:
Youichi Takeyama, Yukei Higashi; St. Marianna Uni-
versity School of Medicine Hospital: Fumihiko Miyake,
Ryouji Kishi, Kiyoshi Nakazawa; St. Marianna University
School of Medicine, Yokohama City Seibu Hospital:
Haruki Musha, Osamu Miyatsu; Teikyo University Hos-
pital: Takaaki Isshiki, Taiji Furukawa; Teikyo University
School of Medicine University Hospital, Mizonokuchi:
Tomoyuki Kunishima; The Hospital of Hyogo College of
Medicine: Mitsumasa Ohyanagi, Hiroki Shimizu; Toho
University Ohashi Medical Center: Kaoru Sugi, Takao
Sakata; Tokyo Medical and Dental University Hospital
Faculty of Medicine: Mitsuaki Isobe, Kenzo Hirao; Tokyo
Metropolitan Hiroo Hospital: Harumizu Sakurada, Tsu-
yoshi Sakai, Hidetaka Okazaki, Akiko Tatsumoto; Toy-
ama University Hospital: Hiroshi Inoue, Tomoki
Kameyama; Tsuchiya General Hospital: Yasuhiko Hay-
ashi, Yuji Muraoka; Yamaguchi University Hospital:
Masunori Matsuzaki, Akihiko Shimizu; Yokohama City
University Medical Center: Kazuo Kimura, Toshiaki
Ebina.
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Appendix 3: List of clinical research coordinators
Asuka Saeki, Hiromi Yoshida, Yuko Yamamoto, Kumiko
Kitagawa, Misato Yamauchi, Naoko Okamoto, Yumika
Fujino, Izumi Miki, Yuki Sato, Yoko Fujiki, Rei Fujita,
Miya Hanazawa, Miho Hayashikawa, Chikako Hibi, Ta-
kami Hiraoka, Sachiko Maeda, Saeko Minematsu, Ayu
Motofusa, Satoko Nishida, Hitomi Sasae, Yayoi Sugimoto,
Emi Takinami, Saori Tezuka, Ayumi Yamamoto, Mai
Yoshimoto.
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